Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
Aged
Animals
Base Sequence
Cell Line, Tumor
Cell Survival
/ drug effects
Drug Synergism
Female
GTP Phosphohydrolases
/ genetics
Genetic Heterogeneity
Humans
Lung Neoplasms
/ diagnosis
Male
Mechanistic Target of Rapamycin Complex 1
/ metabolism
Mechanistic Target of Rapamycin Complex 2
/ metabolism
Membrane Proteins
/ genetics
Mice
Middle Aged
Mitogen-Activated Protein Kinase Kinases
/ antagonists & inhibitors
Models, Biological
Molecular Targeted Therapy
Mutation
/ genetics
Neurosecretory Systems
/ drug effects
Phenotype
Protein Kinase Inhibitors
/ pharmacology
Signal Transduction
Small Cell Lung Carcinoma
/ diagnosis
Smokers
RAS mutation
combination therapy
lung cancers in never smokers
non-neuroendocrine SCLC
small-cell lung cancer
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
27
11
2019
revised:
24
01
2020
accepted:
16
03
2020
pubmed:
20
3
2020
medline:
18
11
2021
entrez:
20
3
2020
Statut:
ppublish
Résumé
Small-cell lung cancer (SCLC) occurs infrequently in never/former light smokers. We sought to study this rare clinical subset through next-generation sequencing (NGS) and by characterizing a representative patient-derived model. We performed targeted NGS, as well as comprehensive pathological evaluation, in 11 never/former light smokers with clinically diagnosed SCLC. We established a patient-derived model from one such patient (DFCI168) harboring an NRAS
Identifiants
pubmed: 32191822
doi: 10.1002/1878-0261.12673
pmc: PMC7782083
doi:
Substances chimiques
Membrane Proteins
0
Protein Kinase Inhibitors
0
Mechanistic Target of Rapamycin Complex 1
EC 2.7.11.1
Mechanistic Target of Rapamycin Complex 2
EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
GTP Phosphohydrolases
EC 3.6.1.-
NRAS protein, human
EC 3.6.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-42Informations de copyright
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
Oncotarget. 2015 Dec 8;6(39):42183-96
pubmed: 26544513
Mol Cancer Ther. 2010 Jul;9(7):1956-67
pubmed: 20571069
Sci Transl Med. 2013 Jul 31;5(196):196ra98
pubmed: 23903755
Nature. 2012 Feb 22;485(7396):55-61
pubmed: 22367541
J Thorac Oncol. 2014 Sep;9(9):1316-23
pubmed: 25122427
J Thorac Oncol. 2016 Aug;11(8):1233-1241
pubmed: 27133774
Cancer Res. 2010 Jan 1;70(1):288-98
pubmed: 20028854
Genes Dev. 2018 Jul 1;32(13-14):915-928
pubmed: 29945888
J Natl Cancer Inst. 2016 May 31;108(10):
pubmed: 27247353
Front Oncol. 2019 Apr 17;9:254
pubmed: 31058075
J Thorac Oncol. 2014 Jun;9(6):892-6
pubmed: 24828667
Arch Pathol Lab Med. 2017 Jun;141(6):751-758
pubmed: 28557599
Cancer Res. 2013 Apr 15;73(8):2574-86
pubmed: 23436801
Clin Cancer Res. 2002 May;8(5):1178-84
pubmed: 12006535
PLoS One. 2016 Jan 28;11(1):e0147682
pubmed: 26821351
Proc Natl Acad Sci U S A. 1983 Apr;80(8):2112-6
pubmed: 6572964
Cancer Cell. 2017 Feb 13;31(2):270-285
pubmed: 28089889
Clin Cancer Res. 2013 May 1;19(9):2584-91
pubmed: 23515407
Nat Genet. 2012 Oct;44(10):1111-6
pubmed: 22941189
Cancer Sci. 2007 Oct;98(10):1638-42
pubmed: 17711503
Cell Death Dis. 2015 Dec 31;6:e2034
pubmed: 26720343
PLoS One. 2014 Sep 02;9(9):e104413
pubmed: 25180793
Nature. 2008 Oct 23;455(7216):1069-75
pubmed: 18948947
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
Cancer Discov. 2016 Jul;6(7):754-69
pubmed: 27154822
Cancer Res. 2010 Nov 1;70(21):8736-47
pubmed: 20959481
Oncogene. 2007 Jul 5;26(31):4596-9
pubmed: 17237811
Nat Genet. 2012 Oct;44(10):1104-10
pubmed: 22941188
Nat Biotechnol. 2011 Oct 30;29(11):1046-51
pubmed: 22037378
Nat Rev Cancer. 2017 Dec;17(12):725-737
pubmed: 29077690
Oncotarget. 2014 Sep 15;5(17):7936-44
pubmed: 25277205
JCI Insight. 2016 Nov 17;1(19):e87062
pubmed: 27882345
Cancer Cell. 2011 Feb 15;19(2):244-56
pubmed: 21316603
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
J Thorac Oncol. 2009 Jan;4(1):37-43
pubmed: 19096304
Mol Cell Biol. 1996 Jul;16(7):3923-33
pubmed: 8668210
J Biol Chem. 2007 May 11;282(19):14056-64
pubmed: 17360704
Oncotarget. 2017 Aug 28;8(43):73745-73756
pubmed: 29088741
Int J Oncol. 2011 Jul;39(1):23-31
pubmed: 21523318
J Clin Invest. 1990 Jun;85(6):1740-5
pubmed: 2161428
Proc Natl Acad Sci U S A. 1988 Sep;85(17):6523-7
pubmed: 2842776
Cancer Res. 1980 Dec;40(12):4356-63
pubmed: 6254644
J Natl Cancer Inst. 2005 Mar 2;97(5):339-46
pubmed: 15741570
ACS Med Chem Lett. 2011 Aug 26;2(10):774-9
pubmed: 24900266
Cancer. 2009 Apr 15;115(8):1723-33
pubmed: 19170230
Sci Transl Med. 2013 Jul 31;5(196):196ra99
pubmed: 23903756
Ann Oncol. 2015 Jan;26(1):161-166
pubmed: 25355724
Oncogene. 2008 Jan 10;27(3):253-63
pubmed: 17637754
Clin Cancer Res. 2013 Apr 15;19(8):2257-64
pubmed: 23444215
Clin Med Insights Oncol. 2012;6:199-203
pubmed: 22619563
Cancer Discov. 2015 Sep;5(9):960-971
pubmed: 26036643
PLoS One. 2011;6(12):e28973
pubmed: 22194965
Mod Pathol. 2012 Jan;25 Suppl 1:S18-30
pubmed: 22214967
Mol Cancer Ther. 2009 Jul;8(7):1725-38
pubmed: 19584227